Washington University
St Louis, Missouri, 63108, United States
Location contact
Gretchen Meyer, PhD
PRINCIPAL_INVESTIGATOR
Mary Hastings, PT, DPT, MSCI, ATC
CONTACT
Mary Hastings, PT, DPT, MSCI, ATC
SUB_INVESTIGATOR
CONTACT
NCT Number: NCT07506681
This study will test the central hypothesis that fat within the muscle, or intramuscular adipose tissue (IMAT), exhibits elevated damage and pro-inflammatory signaling with aging, both of which are reduced by progressive resistance exercise (PRE). Sixteen older adults 65-80 years old will be recruited and complete a 12 week calf PRE intervention. Calf muscle strength, composition (measured by computed tomography) and muscle biopsies will be collected before and after the intervention. Histology, transcriptomic and secretomic tests will be completed to assess signs of damage and inflammation.
Trial opening soon.
Get Notified65 year–80 year
All sexes
Interventional
Not applicable
St Louis, Missouri, 63108, United States
Gretchen Meyer, PhD
PRINCIPAL_INVESTIGATOR
Mary Hastings, PT, DPT, MSCI, ATC
CONTACT
Mary Hastings, PT, DPT, MSCI, ATC
SUB_INVESTIGATOR
CONTACT
Sixteen older adult (65-80 years) will be recruited from existing databases and screened for potential participation by phone. The Rapid Assessment of Physical Activity (RAPA) will be completed, to include those who are underactive (scores 3-5). Individuals who meet the inclusion criteria will attend an in-person screening where their calf muscle strength, physical performance and safety for muscle biopsy (via complete blood count with differential and prothrombin time/international normalized raio on blood draw) will be assessed. Individuals deemed safe to participate and who give informed consent will attend a second visit which will include a computed tomography (CT) scan of the lower leg and ultrasound-guided gastrocnemius muscle+IMAT biopsy. One week later, participants will begin the ankle plantarflexor-targeted progressive resistance exercise (PRE) program which will be delivered in a group Zoom format with a trained therapist 3 times per week for 12 weeks. One week following completion of the PRE program, participants will return for follow-up strength measures, CT, and biopsy. This will complete their participation. In the lab, biopsies will be subdivided for bulk ribonucleic acid sequencing (RNAseq), explant culture and histology. Bulk RNAseq will be used to identify age- and exercise-responsive genes that encode secreted proteins. These putative secreted signals will be validated by protein quantification in explant culture. The cellular origin of validated signals will then be mapped by RNA in situ hybridization (RNAscope) on the portion of the biopsy allocated to histology. Sections will also used to identify senescent cells, inflammatory macrophages and beige adipocytes.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The calf intervention will be delivered 3x/wk for 12 weeks over zoom, in small groups. There are 3 exercises 1) standing heel rise, 2) seated heel rise, and 3) long sitting ankle plantarflexion. The exercises will be overloaded using a weighted vest, body weight, and/or theraband. Exercises will be progressed as strength improves.
Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)
Senescent cells will be identified by expression of β-galactosidase (b-gal) and p16 on histological sections from muscle biopsies. B-gal and p16 positive cells will be counted and normalized to the histological region of interest to obtain a measure of density (# senescent cells / mm^2).
Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)
Muscle volume of the calf and foot will be measured with computed tomography (CT). The participant is supine with leg extended into the (CT). Image post-processing includes removing bones and subcutaneous fat and then segmenting and measuring plantarflexor compartment muscle volume (cm^3).
Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)
Intramuscular fat volume of the calf will be measured with computed tomography (CT). The participant is supine with leg extended into the (CT). Image post-processing includes removing bones and subcutaneous fat and then segmenting and measuring plantarflexor compartment fat volume (cm^3).
Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)
Plantarflexor peak torque of the ankle will be assessed using isokinetic dynamometry. The participant will have a minimum of 3 practice trials to become familiar with the test. The participant will be given 3 minutes of rest and then 3 maximum plantarflexion contractions will be completed, the highest torque produced will be recorded (Newton-meters, Nm).
Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)
Stair climb power will be calculated by multiplying the participant's weight (N)X height of stairs (1.853 meters)/time is takes for them to climb the 10 steps.
Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)
50 foot walking speed (meters/sec) will be measured. Route is 25 feet to a line, turn around, and return to start.
Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)
Physical performance test total score is a composite from the following tests: bilateral feet together stance time, bilateral semi-tandem stance time, and bilateral tandem stance time, five time chair rise time, lift a book to a shelf time, don and doff a jacket time, 360 turn right and left examining stability and continuity, time to pick a nickle off the floor, 50 feet walking speed, stair climb speed. Score ranges from 32 (no fraility) to 0 (severe frailty)
Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)
Adipocyte boundaries will be identified by expression of perilipin on histological sections from muscle biopsies. Adipocyte area will be defined as the area inside a perilipin bounded shape and will be quantified for each adipocyte in the histological region of interest (mm^2).
Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)
Macrophages will be identified by expression of CD206 and CD68 on histological sections from muscle biopsies. CD206 and CD68 positive cells will be counted and normalized to the histological region of interest to obtain a measure of density (# senescent cells / mm^2).
Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)
Beige adipocytes will be identified by expression of UCP1 on histological sections from muscle biopsies. UCP1 positive cells will be counted and normalized to the histological region of interest to obtain a measure of density (# senescent cells / mm^2).
Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)
Differentially expressed genes and pathways will be extracted from RNA sequencing performed on biopsy material (gene count).
Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)
Cytokines will be analyzed in the secreted medium from biopsy material using an antibody based detection method (pg/mL).
Time frame: Baseline and post-intervention (approximately 14 weeks after baseline)
Spatially resolved gene expression will be measured on histological sections using an RNAscope (dots/cell).
Contact information is provided by the study sponsor or research team.
Gretchen Meyer, PhD
CONTACT
Mary Hastings, PT, DPT, MSCI, ATC
CONTACT
Washington University School of Medicine
Other
Targeting Intramuscular Adipose Quality in Aging
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07731529
Aging, Cognition Disorders
Porto Alegre, Rio Grande do Sul, Brazil
View Trial DetailsNCT07674680
Aging, Menopause
Columbia, Missouri, United States
View Trial DetailsNCT07731451
Aging, Aging Well
Flagstaff, Arizona, United States
View Trial DetailsNCT07700654
Aging
Taipei, Taipei City, Taiwan
View Trial Details